Ergothioneine Cognition Meta-analysis: What the Evidence Says

Quick Answer

Ergothioneine Cognition Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 observational study, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Previous studies have associated dementia risk with socioeconomic status (SES), a comprehensive concept that measured a person's position from income, education and occupation. [Zhao Xingguang (2026); evidence level 3]
• Evidence suggests that SES may influence cognitive function through multiple mediating pathways, including lifestyle behaviors, depressive symptoms, and vascular risk factors, highlighting potential targets for interventions to reduce the burden of dementia. [Zhao Xingguang (2026); evidence level 3]
• Cognitive frailty not only affects the quality of life of older adults but also significantly increases the risk of severe adverse outcomes such as dementia and disability. [Gede Arjun M. M. I. (2025); evidence level 3]
• Research has demonstrated that ERGO exhibits significant protective effects against 7-ketocholesterol (7KC)-induced mitochondrial damage in human brain endothelial cells, as evidenced by improved cell viability, reduced intracellular calcium levels, decreased reactive oxygen species, and modulated expression of inflammatory markers. [Gede Arjun M. M. I. (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For ergothioneine cognition meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Zhao Xingguang (2026). Income, diet, and cognitive function: observational analyses and candidate metabolomic pathways identified by Mendelian randomization. DOI: 10.1016/j.tjpad.2026.100582. PMCID: PMC13157074. PMID: 42090781. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13157074/
• Gede Arjun M. M. I. (2025). Advances and prospects of ergothioneine in the treatment of cognitive frailty. DOI: 10.1080/07853890.2025.2555742. PMCID: PMC12416020. PMID: 40914903. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12416020/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.